Month: August 2023

Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023 Biomarker data from VERSATILE-002 to be presented at ESMO 2023 Company to host conference call and webcast today at 8:00 AM EDTPRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, will discuss its financial results for the quarter ended June 30, 2023 and provide a business update on its conference call today. Recent Business Highlights:PDS0101 Lead Drug CandidateVERSATILE-003: Submitted the final Phase 3...

Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portion Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023 On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023 Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLE Closed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash runway into the second half of 2026 Management to host conference call at 8:00 a.m. ET todaySAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug....

BAYPORT MANAGEMENT LTD(Registration number 54787 C1/GBL) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSfor the six months ended 30 June 2023AttachmentGroup Quarterly Report June 23

Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in key efficacy measures, including Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Severity (CGI-S) and Rett Syndrome Behavior Questionnaire (RSBQ), four weeks post-treatment Principal Investigator (PI) observed clinical improvement in multiple domains, including autonomic function (sleep and breathing), vocalization, as well as gross motor skills (gained ability to sit unassisted for three minutes) and fine motor skills (gained ability to hold objects), supported by initial clinical data and video evidence United States (U.S.) Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application...

Fr8Tech Delivers Sturdy Q2 2023 Financial Performance HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT), a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today reports its financial results for the second quarter of 2023, concluding on June 30, 2023. The company has demonstrated steady growth, achieving a 29% increase in revenue compared to the previous quarter and a 93% rise in margin compared to the same year-to-date period last year. Key Financial Highlights: 29% Quarter-over-Quarter Revenue Growth: The company achieved strong revenue growth in the second quarter of 2023, with a noteworthy 29% increase compared...

— UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity — — Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth — — The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company’s portfolio and leverage the field force investment — — Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period, highlighting lower baseline of operating expense — — The Company streamlined operating expense in...

Castellum, Inc. Announces Strong Second Quarter Financial ResultsCastellum, Inc. (NYSE-American: CTM) (the “Company”), a cybersecurity and electronic warfare company focused on the federal government, announces highlights of its operating results for its second quarter ended June 30, 2023 – https://castellumus.com/.BETHESDA, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (the “Company”), a cybersecurity and electronic warfare company focused on the federal government, announces highlights of its operating results for its second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights:Revenues were $12.5 million compared to $9.9 million during the first quarter of 2023. Gross profit was $5.2 million compared to $4 million during the first quarter of 2023. Operating loss,...